How LDL Targets Are Set in the 2026 Cholesterol Guideline

The 2026 ACC/AHA dyslipidemia guideline, published on March 13, 2026, sets low-density lipoprotein (LDL) cholesterol goals that scale with a person's estimated cardiovascular risk rather than applying one universal number. Borderline-to-intermediate-risk primary prevention aims below 100 mg/dL, high risk below 70 mg/dL, and very-high-risk secondary prevention below 55 mg/dL. Those thresholds are not arbitrary. Each one traces back to a chain of randomized trials showing that lower achieved LDL produces proportionally fewer heart attacks and strokes, which is what a guideline is really doing when it prints a target: translating trial data into a decision point.

This article explains that translation. It is educational and not medical advice.

Why the guideline stratifies by risk

The core biological finding behind every modern lipid guideline is disarmingly simple. Across the Cholesterol Treatment Trialists' Collaboration, a pooled analysis of many large statin trials found that each roughly 1 mmol/L (about 39 mg/dL) reduction in LDL cut major vascular events by about one fifth, and that this proportional benefit held across a wide range of people regardless of baseline risk, diabetes status, age, or sex. Lowering LDL by the same amount buys roughly the same percentage risk reduction almost everywhere.

That fact has a subtle consequence. If the percentage benefit is constant, then the absolute benefit depends entirely on how much risk a person carries to begin with. A 20 percent reduction is large for someone with a high near-term event rate and small for someone whose baseline risk is minimal. Risk stratification is the guideline's way of pointing the most aggressive LDL lowering at the people who stand to gain the most in absolute terms, while sparing lower-risk people from intensity that would yield little.

How risk is estimated

To sort people into those tiers, the 2026 guideline adopts the PREVENT equations for estimating 10- and 30-year cardiovascular risk in adults roughly 30 to 79 years old, replacing the older Pooled Cohort Equations. This matters because the earlier equations were understood to overestimate 10-year risk in contemporary populations, which pushed some people toward treatment their actual risk did not justify. Recalibrating the risk estimate changes who lands above each treatment threshold, so the choice of equation is itself part of how the target gets applied. The guideline frames LDL-lowering therapy as reasonable at borderline 10-year risk (roughly 3 to under 5 percent) and recommended after a shared discussion at intermediate risk (roughly 5 to under 10 percent).

Where each LDL number comes from

The three thresholds map onto different bodies of evidence. The below-70 mg/dL goal for high-risk patients reflects trials of more intensive statin therapy, which consistently showed that driving LDL lower than standard doses achieved produced additional event reduction with no loss of the proportional relationship. The below-55 mg/dL goal for very-high-risk secondary prevention rests on a further step: outcomes trials of non-statin agents added on top of statins.

Two lines of evidence anchor that lowest tier. IMPROVE-IT tested ezetimibe added to a statin and found that pushing LDL still lower produced a modest but real further reduction in cardiovascular events, important because it demonstrated benefit from a non-statin mechanism and reinforced that the LDL number, not the drug class, was doing the work. The PCSK9 inhibitor trials extended the same logic to much lower LDL values. In ODYSSEY Outcomes, alirocumab added to intensive statin therapy in post-acute-coronary-syndrome patients reduced LDL substantially and lowered recurrent events, and FOURIER showed a comparable pattern with evolocumab. Newer outcomes data cited in the guideline continue to support intensive lowering toward the below-55 mg/dL range in very-high-risk patients. Taken together, these trials establish that the benefit curve keeps bending downward well past the LDL levels statins alone typically reach.

The treatment cascade as an evidence ladder

The familiar sequence, statin first, then ezetimibe or bempedoic acid, then a PCSK9 monoclonal antibody or inclisiran, is best read as a ladder ordered by evidence strength, tolerability, and cost rather than a rigid protocol. Statins sit at the base because they have the largest and longest outcomes record and are inexpensive. Ezetimibe and bempedoic acid are oral, well tolerated, and supported by outcomes data, making them reasonable next steps when a statin alone does not reach goal.

One notable 2026 change is structural: ezetimibe is no longer a mandatory stop before a PCSK9 monoclonal antibody, and bempedoic acid joins the menu of add-ons. That reflects a shift from a fixed staircase toward matching the size of the remaining LDL gap and the patient's risk to the potency of the next agent. Someone far above goal with very high risk may reasonably move to a potent injectable sooner. The guideline also elevates measuring lipoprotein(a) at least once and using apolipoprotein B and selective coronary artery calcium scoring to refine risk, adding to how a person is placed on the ladder.

Reading a guideline as translation, not instruction

The useful mental model is that a guideline converts a continuous biological relationship, lower LDL means proportionally lower risk, into discrete thresholds and steps that clinicians and patients can act on. Every number embeds a judgment about where added benefit justifies added cost, burden, or uncertainty. Understanding that the below-55, below-70, and below-100 mg/dL goals are calibrated summaries of trial evidence, applied through a risk estimate, makes the recommendations legible rather than mysterious, and clarifies why the same LDL value can be a fine result for one person and a signal to escalate for another.